Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

INTRODUCTION: Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data were available to compare the efficacy of nivolumab to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Batteson, Rachael, Hart, Rose, Hemstock, Matthew, Gooden, Kyna, Kotapati, Srividya, Roze, Stephane, Lee, Dawn, Amadi, Adenike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248152/
https://www.ncbi.nlm.nih.gov/pubmed/31587138
http://dx.doi.org/10.1007/s41669-019-00181-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248152/
https://www.ncbi.nlm.nih.gov/pubmed/31587138
http://dx.doi.org/10.1007/s41669-019-00181-y

Ejemplares similares